2006
DOI: 10.1016/j.jaad.2006.01.007
|View full text |Cite
|
Sign up to set email alerts
|

Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
10
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(10 citation statements)
references
References 38 publications
0
10
0
Order By: Relevance
“…The effect of acitretin 0Á5-1 mg kg À1 per day for up to 3 months is usually a reduction in the bulk of lesions, but with a high risk of recurrence on discontinuation of therapy. 113 In an observational study of children aged [116][117][118][119][120] but it is generally used topically. Topical cidofovir is reconstituted from the parenteral form, as either a 1% or 3% cream.…”
mentioning
confidence: 99%
“…The effect of acitretin 0Á5-1 mg kg À1 per day for up to 3 months is usually a reduction in the bulk of lesions, but with a high risk of recurrence on discontinuation of therapy. 113 In an observational study of children aged [116][117][118][119][120] but it is generally used topically. Topical cidofovir is reconstituted from the parenteral form, as either a 1% or 3% cream.…”
mentioning
confidence: 99%
“…Kottke et al. 5 described clearance of facial warts in a patient with HIV, despite a persistently low CD4 count and high viral loads. Cusack et al.…”
Section: Reportmentioning
confidence: 99%
“…A 21-year-old patient who was immunosuppressed secondary to myelodysplastic syndrome and chemotherapy, had resolution of extensive, widespread warts with cidofovir given over 18 weeks. 4 Kottke et al 5 described clearance of facial warts in a patient with HIV, despite a persistently low CD4 count and high viral loads. Cusack et al 6 reported an 11-year-old girl successfully treated with cidofovir for recalcitrant warts.…”
Section: Reportmentioning
confidence: 99%
See 1 more Smart Citation
“…There is a precedent for using topical cidofovir, 1% and 3%, in dermatology for cutaneous HSV,5 human papillomavirus,6 and molluscum contagiosum 7. Intravenous cidofovir is also used in patients with acyclovir-resistant HSV skin disease 8,9. We decided that IL therapy would provide a more efficient and direct source of medication for this patient’s lesions because his response to the IV cidofovir seemed to be waning.…”
Section: Commentmentioning
confidence: 99%